Products
Online Inquiry
MGCD-265 analog
Cat. No.:
OB0125LY-083
Appearance:
Solid
Purity:
98.6%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
MGCD-265 analog is a multitargeted tyrosine kinase inhibitor that inhibits the activity of multiple receptor tyrosine kinases (RTKs).
Synonym:
875337-44-3; MGCD-265; Glesatinib analog; N-(3-Fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-( (3-Fluoro-4-( (2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)carbamothioyl)-2-phenylacetamide; Benzeneacetamide, N-( ( (3-fluoro-4-( (2-(1-methyl-1H-imidazol-4-yl)thieno (3,2-b)pyridin-7-yl)oxy)phenyl)amino)thioxomethyl)-; N-[[[3-Fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]benzeneacetamide; N-[[3-Fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide; N-[ (3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
CAS No.:
875337-44-3
Compound CID:
24901704
Formula:
C26H20FN5O2S2
Formula Weight:
517.6
Specification
Targets & IC50:
c-Met: 29 nM; VEGFR2: 10 nM
Relative Density:
1.41 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MGCD-265 analog has potential anti-tumor activity that can be used in cancer research.
Library Information
Targets:
Apoptosis; VEGFR; c-Met/HGFR
Receptors:
Apoptosis; c-Met/HGFR; Met; RON; VEGFR; VEGFR1; VEGFR2; VEGFR3
Pathways:
Apoptosis; Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-26
Plate Location:
b10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
96 mg/mL; 185.5 mM
Water Max Solubility:
1 mg/mL
Ethanol Max Solubility:
1 mg/mL
ALogP:
6.037
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
8
